INNOVIVA, INC. Operating Income
INNOVIVA, INC. (INVA) reported Operating Income of $50.85 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- INNOVIVA, INC. operating income (loss) for the quarter ending 2026-06-30 was $50.85M, a 4.32% increase year-over-year.
- INNOVIVA, INC. operating income (loss) for the quarter ending 2026-03-31 was $38.15M, a 7.90% decline year-over-year.
- INNOVIVA, INC. operating income (loss) for the quarter ending 2025-12-31 was $38.99M, a 9.62% decline year-over-year.
- INNOVIVA, INC. operating income (loss) for the quarter ending 2025-09-30 was $34.58M, a 20.03% decline year-over-year.
- INNOVIVA, INC. operating income (loss) for fiscal 2025 was $163.75M, a 1.87% decline from fiscal 2024.
- INNOVIVA, INC. operating income (loss) for fiscal 2024 was $166.87M, a 46.52% increase from fiscal 2023.
- INNOVIVA, INC. operating income (loss) for fiscal 2023 was $113.89M.
- INNOVIVA, INC. operating income (loss) for fiscal 2021 was $375.10M, a 16.81% increase from fiscal 2020.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $50.85M 10-Q · filed 2026-08-05 | $89.01M 10-Q · filed 2026-08-05 | $128.00M derived: sum of 3 quarters · filed 2026-08-05 | $162.57M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $38.15M 10-Q · filed 2026-05-06 | $77.14M derived: sum of 2 quarters · filed 2026-05-06 | $111.72M derived: sum of 3 quarters · filed 2026-05-06 | $160.47M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $38.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $73.57M derived: sum of 2 quarters · filed 2026-02-25 | $122.32M derived: sum of 3 quarters · filed 2026-08-05 | $163.75M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $34.58M 10-Q · filed 2025-11-05 | $83.33M derived: sum of 2 quarters · filed 2026-08-05 | $124.76M 10-Q · filed 2025-11-05 | $167.90M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $48.75M 10-Q · filed 2026-08-05 | $90.18M 10-Q · filed 2026-08-05 | $133.32M derived: sum of 3 quarters · filed 2026-08-05 | $176.56M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $41.43M 10-Q · filed 2026-05-06 | $84.57M derived: sum of 2 quarters · filed 2026-05-06 | $127.80M derived: sum of 3 quarters · filed 2026-05-06 | $182.49M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $43.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $86.38M derived: sum of 2 quarters · filed 2026-02-25 | $141.06M derived: sum of 3 quarters · filed 2026-02-25 | $166.87M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $43.24M 10-Q · filed 2025-11-05 | $97.92M derived: sum of 2 quarters · filed 2025-11-05 | $123.73M 10-Q · filed 2025-11-05 | |||||
| 2024-06-30 | $54.69M 10-Q · filed 2025-08-06 | $80.49M 10-Q · filed 2025-08-06 | ||||||
| 2024-03-31 | $25.80M 10-Q · filed 2025-05-07 | |||||||
| 2023-12-31 | $113.89M 10-K · filed 2026-02-25 | |||||||
| 2022-06-30 | $82.55M 10-Q · filed 2022-07-27 | $160.28M 10-Q · filed 2022-07-27 | $264.81M derived: sum of 3 quarters · filed 2022-07-27 | $359.36M derived: sum of 4 quarters · filed 2022-07-27 | ||||
| 2022-03-31 | $77.73M 10-Q · filed 2022-05-05 | $182.26M derived: sum of 2 quarters · filed 2022-05-05 | $276.81M derived: sum of 3 quarters · filed 2022-05-05 | $373.35M derived: sum of 4 quarters · filed 2022-07-27 | ||||
| 2021-12-31 | $104.53M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $199.08M derived: sum of 2 quarters · filed 2022-03-17 | $295.62M derived: sum of 3 quarters · filed 2022-07-27 | $375.10M 10-K/A · filed 2022-03-17 | ||||
| 2021-09-30 | $94.55M 10-Q · filed 2021-10-27 | $191.09M derived: sum of 2 quarters · filed 2022-07-27 | $270.58M 10-Q · filed 2021-10-27 | $355.36M derived: sum of 4 quarters · filed 2022-07-27 | ||||
| 2021-06-30 | $96.54M 10-Q · filed 2022-07-27 | $176.02M 10-Q · filed 2022-07-27 | $260.81M derived: sum of 3 quarters · filed 2022-07-27 | $345.24M derived: sum of 4 quarters · filed 2022-07-27 | ||||
| 2021-03-31 | $79.48M 10-Q · filed 2022-05-05 | $164.27M derived: sum of 2 quarters · filed 2022-05-05 | $248.70M derived: sum of 3 quarters · filed 2022-05-05 | $324.49M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $84.79M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $169.22M derived: sum of 2 quarters · filed 2022-03-17 | $245.01M derived: sum of 3 quarters · filed 2022-03-17 | $321.12M 10-K/A · filed 2022-03-17 | ||||
| 2020-09-30 | $84.43M 10-Q · filed 2021-10-27 | $160.22M derived: sum of 2 quarters · filed 2021-10-27 | $236.34M 10-Q · filed 2021-10-27 | $309.98M derived: sum of 4 quarters · filed 2021-10-27 | ||||
| 2020-06-30 | $75.79M 10-Q · filed 2021-07-29 | $151.91M 10-Q · filed 2021-07-29 | $225.54M derived: sum of 3 quarters · filed 2021-07-29 | $286.34M derived: sum of 4 quarters · filed 2021-07-29 | ||||
| 2020-03-31 | $76.11M 10-Q · filed 2021-04-28 | $149.75M derived: sum of 2 quarters · filed 2021-04-28 | $210.55M derived: sum of 3 quarters · filed 2021-04-28 | $270.31M derived: sum of 4 quarters · filed 2021-04-28 | ||||
| 2019-12-31 | $73.64M 10-K · filed 2020-02-19 | $134.43M derived: sum of 2 quarters · filed 2020-10-28 | $194.19M derived: sum of 3 quarters · filed 2020-10-28 | $246.36M 10-K/A · filed 2022-03-17 | ||||
| 2019-09-30 | $60.79M 10-Q · filed 2020-10-28 | $120.55M derived: sum of 2 quarters · filed 2020-10-28 | $172.72M 10-Q · filed 2020-10-28 | $249.94M derived: sum of 4 quarters · filed 2020-10-28 | ||||
| 2019-06-30 | $59.76M 10-Q · filed 2020-07-29 | $111.93M 10-Q · filed 2020-07-29 | $189.15M derived: sum of 3 quarters · filed 2020-07-29 | $246.81M derived: sum of 4 quarters · filed 2020-07-29 | ||||
| 2019-03-31 | $52.17M 10-Q · filed 2020-04-29 | $129.39M derived: sum of 2 quarters · filed 2020-04-29 | $187.05M derived: sum of 3 quarters · filed 2020-04-29 | $249.72M derived: sum of 4 quarters · filed 2020-04-29 | ||||
| 2018-12-31 | $77.22M 10-K · filed 2020-02-19 | $134.88M derived: sum of 2 quarters · filed 2020-02-19 | $197.56M derived: sum of 3 quarters · filed 2020-02-19 | $238.25M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $57.66M 10-K · filed 2020-02-19 | $120.34M derived: sum of 2 quarters · filed 2020-02-19 | $161.03M 10-Q · filed 2019-10-30 | $227.44M derived: sum of 4 quarters · filed 2020-02-19 | ||||
| 2018-06-30 | $62.67M 10-K · filed 2020-02-19 | $103.37M 10-Q · filed 2019-07-24 | $169.78M derived: sum of 3 quarters · filed 2020-02-19 | $209.80M derived: sum of 4 quarters · filed 2020-02-19 | ||||
| 2018-03-31 | $40.70M 10-K · filed 2020-02-19 | $107.10M derived: sum of 2 quarters · filed 2020-02-19 | $147.13M derived: sum of 3 quarters · filed 2020-02-19 | $194.96M derived: sum of 4 quarters · filed 2020-02-19 | ||||
| 2017-12-31 | $66.41M 10-K · filed 2019-02-19 | $106.43M derived: sum of 2 quarters · filed 2019-02-19 | $154.26M derived: sum of 3 quarters · filed 2019-02-19 | $183.60M 10-K · filed 2020-02-19 | ||||
| 2017-09-30 | $40.02M 10-K · filed 2019-02-19 | $87.85M derived: sum of 2 quarters · filed 2019-02-19 | $117.19M 10-Q · filed 2018-10-31 | $154.86M derived: sum of 4 quarters · filed 2019-02-19 | ||||
| 2017-06-30 | $47.83M 10-K · filed 2019-02-19 | $77.17M 10-Q · filed 2018-07-26 | $114.83M derived: sum of 3 quarters · filed 2019-02-19 | $142.75M derived: sum of 4 quarters · filed 2019-02-19 | ||||
| 2017-03-31 | $29.34M 10-K · filed 2019-02-19 | $67.00M derived: sum of 2 quarters · filed 2019-02-19 | $94.92M derived: sum of 3 quarters · filed 2019-02-19 | $120.80M derived: sum of 4 quarters · filed 2019-02-19 | ||||
| 2016-12-31 | $37.66M 10-K · filed 2018-02-23 | $38.02M 10-K · filed 2017-02-28 | $65.58M derived: sum of 2 quarters · filed 2018-02-23 | $91.46M derived: sum of 3 quarters · filed 2018-02-23 | $108.99M 10-K · filed 2019-02-19 | |||
| 2016-09-30 | $27.92M 10-K · filed 2018-02-23 | $53.80M derived: sum of 2 quarters · filed 2018-02-23 | $71.33M 10-Q · filed 2017-11-03 | $88.62M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-06-30 | $25.88M 10-K · filed 2018-02-23 | $43.41M 10-Q · filed 2017-08-08 | $60.70M derived: sum of 3 quarters · filed 2018-02-23 | $69.14M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-03-31 | $17.53M 10-K · filed 2018-02-23 | $34.83M derived: sum of 2 quarters · filed 2018-02-23 | $43.26M derived: sum of 3 quarters · filed 2018-02-23 | $48.37M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2015-12-31 | $17.29M 10-K · filed 2017-02-28 | $25.73M derived: sum of 2 quarters · filed 2017-02-28 | $30.84M derived: sum of 3 quarters · filed 2017-02-28 | $31.58M 10-K · filed 2018-02-23 | ||||
| 2015-09-30 | $8.43M 10-K · filed 2017-02-28 | $13.54M derived: sum of 2 quarters · filed 2017-02-28 | $14.29M 10-Q · filed 2016-11-03 | $14.42M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-06-30 | $5.11M 10-K · filed 2017-02-28 | $5.85M 10-Q · filed 2016-08-04 | $5.98M derived: sum of 3 quarters · filed 2017-02-28 | -$3.56M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-03-31 | $745.00K 10-K · filed 2017-02-28 | $875.00K derived: sum of 2 quarters · filed 2017-02-28 | -$8.67M derived: sum of 3 quarters · filed 2017-02-28 | -$18.46M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2014-12-31 | $130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$9.41M derived: sum of 2 quarters · filed 2017-02-28 | -$19.21M derived: sum of 3 quarters · filed 2017-02-28 | -$33.93M 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | -$9.54M 10-Q · filed 2015-11-05 | -$19.34M derived: sum of 2 quarters · filed 2015-11-05 | -$34.06M 10-Q · filed 2015-11-05 | -$41.48M derived: sum of 4 quarters · filed 2016-02-24 | ||||
| 2014-06-30 | -$9.79M 10-Q · filed 2015-08-06 | -$24.52M 10-Q · filed 2015-08-06 | -$31.93M derived: sum of 3 quarters · filed 2016-02-24 | -$39.64M derived: sum of 4 quarters · filed 2016-02-24 | ||||
| 2014-03-31 | -$14.72M 10-Q · filed 2015-05-08 | -$66.24M 10-Q · filed 2014-05-07 | -$22.14M derived: sum of 2 quarters · filed 2016-02-24 | -$29.85M derived: sum of 3 quarters · filed 2016-02-24 | -$36.74M derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2013-12-31 | -$7.42M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | -$15.12M derived: sum of 2 quarters · filed 2016-02-24 | -$22.02M derived: sum of 3 quarters · filed 2016-02-24 | -$28.80M 10-K · filed 2016-02-24 | -$168.86M 10-K · filed 2014-03-03 | |||
| 2013-09-30 | -$7.71M 10-Q · filed 2014-11-04 | -$45.24M 10-Q · filed 2013-11-01 | -$14.61M derived: sum of 2 quarters · filed 2014-11-04 | -$21.38M 10-Q · filed 2014-11-04 | -$120.41M 10-Q · filed 2013-11-01 | -$90.12M derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-06-30 | -$6.90M 10-Q · filed 2014-08-07 | -$41.79M 10-Q · filed 2013-08-01 | -$13.67M 10-Q · filed 2014-08-07 | -$75.17M 10-Q · filed 2013-08-01 | -$82.41M derived: sum of 3 quarters · filed 2015-02-27 | -$115.76M derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-03-31 | -$33.39M 10-Q · filed 2014-05-07 | -$75.51M derived: sum of 2 quarters · filed 2015-02-27 | -$108.86M derived: sum of 3 quarters · filed 2015-02-27 | -$144.57M derived: sum of 4 quarters · filed 2015-02-27 | ||||
| 2012-12-31 | -$42.13M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | -$75.48M derived: sum of 2 quarters · filed 2015-02-27 | -$111.19M derived: sum of 3 quarters · filed 2015-02-27 | -$25.15M 10-K · filed 2015-02-27 | -$13.00M 10-K · filed 2013-02-26 | |||
| 2012-09-30 | -$33.35M 10-Q · filed 2013-11-01 | -$69.06M derived: sum of 2 quarters · filed 2013-11-01 | $16.98M 10-Q · filed 2013-11-01 | -$18.59M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2012-06-30 | -$35.71M 10-Q · filed 2013-08-01 | $50.33M 10-Q · filed 2013-08-01 | $14.76M derived: sum of 3 quarters · filed 2014-03-03 | -$14.45M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2012-03-31 | $86.04M 10-Q · filed 2013-05-01 | $50.47M derived: sum of 2 quarters · filed 2014-03-03 | $21.26M derived: sum of 3 quarters · filed 2014-03-03 | -$2.39M derived: sum of 4 quarters · filed 2014-03-03 | ||||
| 2011-12-31 | -$35.58M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$64.78M derived: sum of 2 quarters · filed 2014-03-03 | -$88.43M derived: sum of 3 quarters · filed 2014-03-03 | -$109.74M 10-K · filed 2014-03-03 | ||||
| 2011-09-30 | -$29.20M 10-Q · filed 2012-10-31 | -$52.86M derived: sum of 2 quarters · filed 2012-10-31 | -$74.16M 10-Q · filed 2012-10-31 | -$92.09M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | -$23.66M 10-Q · filed 2012-08-01 | -$44.96M 10-Q · filed 2012-08-01 | -$62.89M derived: sum of 3 quarters · filed 2013-02-26 | -$82.74M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | -$21.30M 10-Q · filed 2012-05-02 | -$39.23M derived: sum of 2 quarters · filed 2013-02-26 | -$59.08M derived: sum of 3 quarters · filed 2013-02-26 | -$78.51M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | -$17.93M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$37.78M derived: sum of 2 quarters · filed 2013-02-26 | -$57.21M derived: sum of 3 quarters · filed 2013-02-26 | -$78.32M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | -$19.84M 10-Q · filed 2011-11-02 | -$39.28M derived: sum of 2 quarters · filed 2011-11-02 | -$60.39M 10-Q · filed 2011-11-02 | |||||
| 2010-06-30 | -$19.43M 10-Q · filed 2011-08-03 | -$40.55M 10-Q · filed 2011-08-03 | ||||||
| 2009-12-31 | -$81.36M 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |